Interestingly, subcutaneous IL-1Ra application in ischemic stroke patients within 5 h of symptom onset in the SCIL-STROKE Phase 2 trial also observed a reduction of IL-6 and CRP after treatment without reporting any safety concerns [141]. The gene discussed is CRP; the disease is ischemic stroke.